2015-02-17

Suppression of systemic autoimmunity by the innate immune adaptor STING

Shrutie Sharma
University of Massachusetts Medical School

Allison M. Campbell
Yale University

Jennie Chan
University of Massachusetts Medical School

See next page for additional authors

Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_sp

Part of the Immune System Diseases Commons, Immunity Commons, and the Skin and Connective Tissue Diseases Commons

Repository Citation
Sharma, Shruti; Campbell, Allison M.; Chan, Jennie; Schattgen, Stefan A.; Orlowski, Gregory M.; Nayar, Ribhu; Huyler, Annie H.; Nundel, Kerstin; Mohan, Chandra; Berg, Leslie J.; Shlomchik, Mark J.; Marshak-Rothstein, Ann; and Fitzgerald, Katherine A., "Suppression of systemic autoimmunity by the innate immune adaptor STING" (2015). GSBS Student Publications. 2012.
https://escholarship.umassmed.edu/gsbs_sp/2012

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Student Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
Suppression of systemic autoimmunity by the innate immune adaptor STING

Authors

Keywords
IRF3, STING, TLRs, autoimmunity, lupus

Rights and Permissions
Publisher PDF posted as allowed by the publisher's author rights policy at http://www.pnas.org/site/aboutpnas/authorfaq.xhtml.

This article is available at eScholarship@UMMS: https://escholarship.umassmed.edu/gsbs_sp/2012
Suppression of systemic autoimmunity by the innate immune adaptor STING

Shruti Sharma*, Allison M. Campbellb,1, Jennie Chana,1, Stefan A. Schattenbg,1, Gregory M. Orlovskia,1, Ribhu Nayarb, Annie H. Huylerb, Kerstin Nündelb, Chandra Mohanca, Leslie J. Bergd, Mark J. Shlomchick, Ann Marshak-Rothsteina,2,3, and Katherine A. Fitzgeralda,2,3

*Program in Innate Immunity, Division of Infectious Diseases, Department of Pathology, and 1Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605; 2Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT 06519; 3Department of Immunology and Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390; 4Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, 7469 Trondheim, Norway

Edited by Ruslan Medzhitov, Yale University School of Medicine, New Haven, CT, and approved January 7, 2015 (received for review October 23, 2014)

Cytosolic DNA-sensing pathways that signal via Stimulator of interferon genes (STING) mediate immunity to pathogens and also promote autoimmune pathology in DnaseI- and DnaseIII-deficient mice. In contrast, we report here that STING potently suppresses inflammation in a model of systemic lupus erythematosus (SLE). Lymphoid hypertrophy, autoantibody production, serum cytokine levels, and other indicators of immune activation were markedly decreased in STING-deficient autoimmune-prone mice compared with STING-sufficient littermates. As a result, STING-deficient autoimmune-prone mice had significantly shorter lifespans than controls. Importantly, Toll-like receptor (TLR)-dependent systemic inflammation during 2,6,10,14-tetramethylpentadecane (TMPD)-mediated peritonitis was similarly aggravated in STING-deficient mice. Mechanistically, STING-deficient macrophages failed to express negative regulators of immune activation and thus were hyperresponsive to TLR ligands, producing abnormally high levels of proinflammatory cytokines. This hyperreactivity corresponds to dramatically elevated numbers of inflammatory macrophages and granulocytes in vivo. Collectively these findings reveal an unexpected negative regulatory role for STING, having important implications for STING-directed therapies.

STING | autoimmunity | IRF3 | lupus | TLRs

The detection of microbial DNA and the production of type I IFNs and proinflammatory cytokines is a central component of host defense. The pattern recognition receptor Toll-like receptor (TLR) 9 detects DNA that accumulates in endolysosomal compartments. In addition, newly described cytosolic DNA sensors [cyclic guanosine monophosphate adenosine monophosphate synthase (cGAS) and IFN inducible protein 16 (IFI16), among others], detect DNA in the cytosol (1, 2). Each of these cytosolic sensors converges on the multipass transmembrane endoplasmic reticulum-associated protein, Stimulator of IFN genes (STING) (also known as “TMEM173,” “MPYS,” “MITA,” and “ERIS”) (3, 4). STING is considered a critical hub, in cytosolic DNA-sensing pathways, for innate responses directed against numerous bacterial, viral, and parasitic pathogens (4). STING activates host defense via induction of IFN-β through a well-characterized pathway involving TBK1 and interferon regulatory factor 3 (IRF3) (4) and the production of the NF-κB-driven cytokines TNF-α and IL-6 (3).

STING-dependent cytosolic sensors also detect endogenous ligands, as first shown by polymorphisms in DnaseIII (3′ repair exonuclease 1, Trex1) and related enzymes associated with DNA degradation in patients with autoimmune diseases (5–7). Trex1-deficient mice fail to degrade endogenous DNA, resulting in type I IFN and proinflammatory cytokine production and sterile inflammation (8, 9). Importantly, STING deficiency limits inflammation in the above model. However, its role in more common systemic autoimmune diseases such as systemic lupus erythematosus (SLE) has not yet been investigated.

To understand the impact of cytosolic DNA-sensing pathways in SLE, we intercrossed STING-deficient mice with the SLE-prone strain MRL Fas/lpr and compared disease parameters in STING-deficient and STING-sufficient Fas/lpr littermates. Our analysis reveals a previously undescribed role for STING as a negative regulator of TLR-mediated systemic autoimmunity, as the STING−/− MRL.Fas/lpr mice developed more severe disease and accelerated mortality. STING−/− mice subjected to 2,6,10,14-tetramethylpentadecane (TMPD)-induced acute peritonitis also display aggravated inflammation. Both models are driven by endosomal TLRs; therefore it was particularly interesting to find that STING-deficient macrophages were hyperresponsive to TLR ligands. Collectively, our findings highlight unappreciated cross-talk between TLR and cytosolic nucleic acid-sensing pathways in maintaining immune homeostasis and raise a cautionary note about targeting the STING pathway in chronic inflammation.

Results

STING Deficiency Accelerates Lymphocyte Accumulation and Activation During Lupus. We generated two cohorts of autoimmune-prone mice by intercrossing MRL.Fas/lpr mice with either STING- or IRF3-deficient strains. This strategy led to the generation of F2

Significance

Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease that presents with a diverse array of clinical symptoms and afflicts over 1.5 million Americans. Current treatments involve immunosuppressive regimens associated with debilitating and adverse effects. With the description of a role for innate signaling in SLE, safe and efficient therapies that block Toll-like receptors also have been stymied by the relative short in vivo half lives of known inhibitors and the dangerous outcome of complete MyD88 blockade. Key natural regulators of the disease process are not well described but are more likely to provide disease-specific therapeutics with fewer adverse effects. In this study, we have identified a novel function for Stimulator of interferon genes as a suppressor of disease and a target for future SLE therapeutics.


The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

1A.M.-C., J.C., S.A.S., and G.M.O. contributed equally to this work.
2A.M.-R. and K.A.F. contributed equally to this work.
3To whom correspondence may be addressed. Email: ann.rothstein@umassmed.edu or kate.fitzgerald@umassmed.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1420217112/-/DCSupplemental.

www.pnas.org/cgi/doi/10.1073/pnas.1420217112

PNAS www.pnas.org E710-E717 | PNAS | Published online February 2, 2015

www.pnas.org/cgi/doi/10.1073/pnas.1420217112
mice that were Fas+/− homozygotes and either STING−/− or IRF3−/− (hereafter referred to as “STING/lpr” and “IRF3/lpr,” respectively) as well as Fas+/+ Fas−/− STINGWT/WT or IRF3WT/WT (referred to as “WT/lpr”). MRL/Fas−/− mice routinely develop clinical features of SLE associated with lymphoid hypertrophy by 20–24 wk of age. However, by 16 wk of age the STING/lpr offspring displayed markedly greater splenomegaly and lymphadenopathy and higher splenocyte numbers than their STING-sufficient WT/lpr littersmates (Fig. 1 A and B). Fas+/+ Fas−/− STING−/− (Het) littersmates resembled the WT/lpr cohort. In contrast, the IRF3/lpr mice did not show any alteration in disease progression compared with control WT/lpr mice, and the splenic compartments were identical in composition and size (Fig. 1 A and B). Moreover, the frequency and total number of the unusual CD4/CD8 double-negative (DN) TCRβ+ B220+ T-cell subset, characteristic of Fas−/− Fas−/− mice (10), was increased significantly in the STING/lpr mice (Fig. 1 C and Fig. S1B). STING/lpr mice also had larger numbers of total and activated CD44+ CD69+ B220+ T cells and TCRβ+ B cells (Fig. 1 D and Fig. S1C). IRF3/lpr mice did not display any overt expansion of naive or activated T cells in their peripheral lymphoid organs (Fig. S1D). Importantly, STING−/− Fas-sufficient littersmates (STING/WT) showed no evidence of lymphoid hypertrophy or immune activation. Additionally, the sex of the STING/lpr mice did not significantly alter the severity of disease, because both male and female STING/lpr mice showed similarly aggravated disease manifestations (Fig. S1E). Thus, STING restricts unchecked immune activation during systemic autoimmune disease and does so in an IRF3-independent manner.

**STING Deficiency Leads to Increased Autoantibody Production.** Antinuclear antibodies (ANAs) are hallmarks of SLE (11). MRL/Fas−/− mice normally make autoantibodies against both RNA- and DNA-associated autoantigens (12, 13). Importantly, STING/lpr, but not IRF3/lpr, mice had more B220+ CD138+ plasma cells than WT/lpr mice as well as a significantly greater incidence of IgG class-switched antibody-producing cells as determined by ELISPOT (Fig. 2 A and Fig. S1F). To comprehensively compare autoantibody specificity and titers of the STING/lpr and WT/lpr mice, we used autoantigen microarrays (14). This analysis showed an overall increase in autoantibody titers in the STING/lpr sera, compared with WT/lpr littersmates, especially with regard to autoantigens commonly associated with SLE such as DNA, histones, chromatin, small nuclear ribonucleoproteins, C1q, granulocyte markers, and extracellular matrix (Fig. 2B). Notably, the reactivity of sera from the 16-wk-old STING/lpr mice was markedly elevated compared with sera from age-matched WT/lpr littersmates and more closely resembled the sera from 25-wk-old WT/lpr littersmates.

**STING Deficiency but Not IRF3 Deficiency Leads to Accelerated Mortality, Lupus Nephritis, and Gross Morbidity in the MRL/Fas−/− Model.** In agreement with their disease severity, STING/lpr mice exhibited more extensive renal disease than their WT/lpr littersmates, as determined both by proteinuria and histological examination of the kidneys at 16 wk of age (Fig. 3 A and B). Histological examination of the STING/lpr kidneys showed a greater degree of mononuclear and lymphocytic infiltrates (Fig. 3B, a–c), substantial protein deposition, and thickening of the basement membranes (Fig. 3B, d–f). Overall the STING/lpr mice had significantly higher nephritis scores (Fig. 3C), whereas the IRF3/lpr mice showed no signs of accelerated renal disease (Fig. 3D). Importantly, more severe nephritis was associated with significantly accelerated mortality in the STING/lpr mice. The median age at death was 17.5 wk for STING/lpr mice compared with 26 wk for the WT/lpr mice (P = 0.0037) (Fig. 3E).

**STING Deficiency but Not IRF3 Deficiency Leads to the Expansion of Unusual Inflammatory Myeloid and Dendritic Cell Populations.** Although STING is expressed ubiquitously, its expression in myeloid cells is closely tied to its role in innate responses (3, 15). Intriguingly, the number and activation status of myeloid cells (CD11b+ or CD11c+) in the STING/lpr spleens was increased greatly compared with WT/lpr littersmates (Fig. 4 A and B and Fig. S2A). Within the myeloid compartment, CD11b+ Ly6Chigh cells are considered a highly inflammatory class of monocytes, and the Ly6Ghi/Ly6Cint subset consists of inflammatory neutrophils (16). Both subsets are characterized by their association...
Increased numbers of antibody-producing cells and accelerated antibody production in STING-deficient autoimmune-prone mice. (A, Left) Percentage of B220+CD138+ plasma cells as determined by FACS analysis. (Right) Total number of antibody-forming cells (AFCs) quantified by ELISPOT analysis. Data are presented as mean ± SEM. P values as noted (Student’s t test). (B) Autointoactivity specificity and titers were determined by binding of sera from WT/lpr (n = 9) and STING/lpr (n = 9) littermates to a predefined autoantigen array. Data are presented as a heatmap summarizing IgM and IgG reactivities. Each column lane represents an individual mouse. Mice were 16 or 25 wk old; asterisks indicate 25-wk-old mice.

with an inflammatory milieu and are thought to give rise to cells that participate heavily in tissue destruction and remodeling (17, 18). Notably, STING/lpr mice showed a significant expansion and activation of both Ly6C− inflammatory monocyte (R1) and Ly6C hi inflammatory monocyte (R1) and Ly6G hi granulocytes in the spleens of pristane-treated Unc93b−/− mice (Fig. 5 A). In contrast, the percentage of Ly6C− inflammatory monocytes in the peritoneum, the percentage of Ly6C hi Ly6G− granulocytes was significantly higher in the spleens of the TMPD-injected STING−/− mice than in controls (Fig. 5C). The accumulation of inflammatory granulocytes in the spleens of pristane-treated mice at 6 mo post-injection has been reported previously (16); however, to our knowledge, this is the first report of such an early signature of kines and cytokines including the M1-associated cytokines TNF-α and IL-6 and chemokines (CCL2, CCL5, CXCL1, CCL3, and CCL4) (Fig. 4D and Fig. S2G). Of note, IL-9 and IL-3 correlate with the proliferation and differentiation of neutrophilic progenitor cells (19, 20), and increased systemic levels of IL-9 and IL-3 correlate directly with the myeloid expansion seen in STING/lpr mice (Fig. 4D). Together these data highlight the previously unrecognized role that STING normally plays in limiting the expansion and activity of pathogenic myeloid populations in systemic autoimmune diseases such as SLE.

**STING Deficiency Results in the Increased Expression of IFN-Stimulated Genes and IFN-α–Secreting Cell Populations.** Type I IFNs have been shown to play a significant role in SLE (21). Therefore it was essential to determine whether the IFN signature was altered in the STING/lpr mice. Gene-expression profiling of STING/lpr and WT/lpr splenocytes showed a significant increase in the expression of IFN-stimulated genes (ISGs) in STING/lpr spleens compared with WT/lpr littermates, as is consistent with disease severity but paradoxical with STING deficiency (Fig. 4E). An up-regulated ISG signature generally is indicative of increased levels of type I IFNs and IFN-producing cells in the periphery. Plasmacytoid dendritic cells (pDCs) are thought to be the major type 1 IFN-producing cell (IPC) in both murine models of SLE and in human patients, although other myeloid and lymphoid lineage cells also are known contributors (22, 23). Importantly, the number of pDCs identified as CD11c+Siglec-H+Bst2+ (Fig. S3A) was increased significantly in the spleens from STING/lpr mice but not in the IRF3/lpr spleens (Fig. S3B). By using intracellular staining, we identified not only increased numbers of IFN-α–producing pDCs but also IFN-α–producing Ly6C hi and Ly6C lo monocytes in STING/lpr mice (Fig. 4 F and G and Fig. S3C). IFN-α–producing Ly6C hi monocytes have been found at the site of viral infections as well as in inflammatory diseases such as colitis (18). However, the increase in IFN-α–producing Ly6C hi cells was surprising (Fig. 4G), because these subsets have not been identified previously as sources of type 1 IFN in SLE or other diseases. This finding suggests that typical and atypical IFN-α–producing pathways are significantly dysregulated in the absence of STING.

**TMPD-Induced Peritonitis Is Amplified by STING Deficiency.** Several key features of SLE are recapitulated by the i.p. injection of the hydrocarbon oil TMPD (also known as “pristane”). These features include a type I IFN signature, ANAs, and glomerulonephritis (24, 25). Importantly, TMPD-induced autoimmunity is dependent upon TLR7 and type I IFNs (26). Pristane injection of C57Bl/6 mice results in an early and persistent peritoneal inflammation and the recruitment of TLR7+Ly6C hi monocytes, a potential source of type I IFNs, in this model (25). We thus sought to determine if TMPD-induced, TLR-dependent inflammation is also modulated by STING. The extravasation of inflammatory monocytes and granulocytes into the peritoneal cavity following TMPD administration was entirely dependent on endosomal TLRs, because no evidence of inflammation occurred in pristane-treated Unc93b−/− mice (Fig. 5A). In comparison, STING−/− mice showed greater accumulation of total cells, CD11b+ myeloid cells, and especially CD11b + Ly6C hi inflammatory monocytes. The expression of ISGs (IRF7 and Mx1) was also increased in the peritoneal exudate cells (PECs) from STING−/− mice but not Unc93b−/− mice (Fig. 5B), again implying type I IFN in pathology. Although there was no significant increase in the number of Ly6C hi Ly6C hi granulocytes in the peritoneum, the percentage of Ly6C hi Ly6C lo granulocytes was significantly higher in the spleens of the TMPD-injected STING−/− mice than in controls (Fig. 5C). The accumulation of inflammatory granulocytes in the spleens of pristane-treated mice at 6 mo post-injection has been reported previously (16); however, to our knowledge, this is the first report of such an early signature of
systemic inflammation. These data document a second example in which STING negatively regulates a TLR-dependent inflammatory response.

**Macrophages Derived from STING-Deficient Mice Are Hyperresponsive to TLR7 and TLR9 Ligands.** In all SLE models evaluated to date, immune activation depends on the ability of endogenous TLRs to recognize nucleic acid-associated autoantigens (25, 27). Therefore, we reasoned that STING/lpr-derived macrophages could be inherently more reactive to such autoantigens via TLR7- and/or TLR9-dependent pathways. To test this possibility directly, bone marrow-derived macrophages (BMMs) from STING/lpr and WT/lpr mice were stimulated with TLR7 and TLR9 ligands. As expected, STING/lpr macrophages failed to produce the proinflammatory cytokines TNF-α and IL-6 in response to TLR ligands but were hyperresponsive to TLR7 and TLR9 ligands (Fig. 6). To confirm that this increase actually was caused by STING deficiency alone and not by other MRL-associated genes, we also compared STING-deficient and STING-sufficient C57BL/6 BMMs (Fig. S4A). Again the STING−/− BMMs were hyperresponsive to TLR7 and TLR9 ligands, despite impaired responses to ISD or B-form DNA (pdAdT). Moreover, STING−/− BMMs made significantly more IL-6 in response to limiting concentrations of TLR7/9 ligands (Fig. 6B) as well as additional TLR ligands (Fig. S4B). In addition, TLR3 stimulation of STING−/− BMMs resulted in elevated levels of IFN-β (Fig. S4C). Thus, more than one pathway, downstream of TLRs, is modified by STING deficiency.

**STING Deficiency but Not IRF3 Deficiency Results in Reduced Levels of Known Negative Regulators of TLR Signaling.** STING deficiency could lead to amplified activation of TLR-dependent macrophage responses either by increasing the level of TLR expression or by decreasing negative regulation of TLR signaling. We compared basal levels of endosomal TLRs in WT, STING−/−, WT/lpr, and STING/lpr BMMs but found no difference in TLR3, TLR7, or TLR9 expression (Fig. S5A). Surprisingly, unstimulated STING−/− BMMs had dramatically decreased expression of several well-characterized negative regulators of TLR signaling, including A20 and suppressor of cytokine signaling 1 (SOCS1) and 3 (SOCS3), compared with WT controls (Fig. 6C and D). Importantly, these genes are not regulated through an IRF3-dependent mechanism, because IRF3−/− BMMs did not display any change in basal expression levels of these critical negative regulators (Fig. 6C). Levels of A20, SOCS1, and SOCS3 were also decreased substantially in activated STING−/− BMMs (Fig. S5B). Similar analysis of STING/lpr- and WT/lpr-derived BMMs revealed significantly attenuated A20, SOCS1, and SOCS3 levels basally and in response to TLR ligands (Fig. 6E and Fig. S5C). Furthermore, gene profiling of STING/lpr and WT/lpr splenic tissue also revealed a significant decrease in the expression of these negative regulators (Fig. 6E). To confirm that the expression of these negative regulators was regulated directly by STING, we determined the effect of STING overexpression on these genes. We found that stable overexpression of STING in RAW264.7 macrophage cells resulted in elevated basal levels of A20, SOCS1, and SOCS3 levels basally and in response to TLR ligands (Fig. 6F). Moreover, ectopic expression of STING reduced the production of TNF-α and IL-6 in response to TLR ligands but not in response to cytosolic DNA ligands (Fig. S5D).

Secreted negative regulators of immune responses also contribute to self-tolerance. Recent studies have shown that myeloid cell production of Indoleamine 2,3-deoxygenase-1 (IDO-1), particularly by dendritic cells (DCs), promotes the conversion and expansion of regulatory T cells (28). When spleen sections from 16-wk-old STING/lpr and WT/lpr littermates were stained...
with anti-IDO-1 antibody, spleens from STING/lpr mice had greatly reduced IDO-1 levels compared with age-matched littermate controls (Fig. 6G). Because IDO-1 is thought to control the generation of Treg cells, we determined the number of Treg cells in STING/lpr and control mice. We found that STING/lpr mice had significantly lowered percentages of activated CD4+ CD25+ FOXP3+ Treg cells and also tended toward lowered percentages of CD4+ FOXP3+ Treg cells in axillary lymph nodes (Fig. 6H). These data, along with other recent studies (29), explain how immune suppression in STING−/− animals may be systemically compromised. Overall, these data strongly indicate that in the context of an SLE autoimmune-prone background, STING-deficient myeloid cells mount an amplified response to nucleic acid-associated autoantigens caused by the reduced expression of molecules that directly or indirectly limit immune activation.

**Discussion**

Foreign DNA can trigger both endosomal TLR9 and cytosolic STING-dependent DNA sensors, leading to the robust production of type I IFNs and other proinflammatory cytokines important in the clearance of microbial pathogens. Chronic stimulation of these sensors by endogenous ligands also provokes debilitating auto-inflammatory or autoimmune diseases such as seen in mice or humans with compromised capacities to degrade DNA. In contrast to experimental settings where STING provokes inflammation, our studies show that STING can attenuate inflammation in both a chronic systemic autoimmune disease and in an acute inflammatory response that is dependent on TLR-mediated detection of endogenous ligands. STING-deficient MRL/lpr mice develop a dramatically accelerated disease profile characterized by the expansion and activation of both the lymphoid and myeloid compartments, increased numbers of type I IFN-producing cells, elevated autoantibody titers, and a shorter lifespan. Similar to our findings in the MRL/lpr model, STING deficiency exacerbated TMDP-induced inflammation, a condition also associated with type I IFNs and TLR-activated Ly6C<sup>hi</sup> monocytes (24, 26).

Nonautoimmune-prone STING-deficient mice do not exhibit any evidence of systemic autoimmunity. Therefore, the exacerbated disease phenotype of the STING-deficient MRL/lpr mice likely results from the failure to constrain aberrantly activated TLR signaling cascades responsible for disease. Intriguingly, A20−, SOCS1−, or SOCS3-deficient mice exhibit phenotypes similar to our STING/lpr mice (30, 31). In addition to impaired expression...
of these negative regulators of TLR activation, STING/lpr mice also failed to express the secreted immunosuppressive protein IDO-1. Previous studies documented IDO-1 expression in the spleens of prediseased MRL.Fas<sup>+</sup> mice and its reduced expression with disease progression (32). Moreover, treatment with an IDO-1 inhibitor 1-methyl tryptophan (1-MT) accelerates disease in the MRL.Fas<sup>−/−</sup> mice, implicating IDO-1 in the negative regulation of immune activation associated with autoimmunity. Because IDO-1 is potently induced by TLR-dependent and -independent pathways and regulates the expansion of Tregs, it is a critical factor in limiting disease severity (28). Recently, Huang et al. (33) showed that IDO-1 expression in DCs is attenuated in the absence of STING, leading to increased IL-6 production by STING<sup>−/−</sup> DCs in response to apoptotic cells. We now show decreased IDO-1 levels and a corresponding decrease in Treg cells in STING-deficient SLE-prone mice. These conditions are likely to contribute to the exacerbated disease phenotype.

A seemingly unrelated outcome of disease in the STING/lpr mice is the large number of monocytic cells in secondary lymphoid tissues. However, monocyte egress from the bone marrow and local proliferation is a known consequence of TLR engagement (34). Whether increased TLR activity also contributes to the excess production of the hematopoiesis-modulating cytokines IL-9 and IL-3, thereby further promoting myeloid expansion in STING<sup>−/−</sup> mice; both strains show elevated expression of ISGs and marked expansion and activation of lym}

![Fig. 5. STING deficiency exacerbates TMPD-induced TLR and type I IFN-dependent inflammation. (A) Comparison of the total numbers of PECs and cellular subsets 2 wk after TMPD treatment in C57Bl/6, STING<sup>−/−</sup>, Unc93b<sup>−/−</sup>, and PBS-injected mice. Total numbers of CD11b<sup>+</sup>, Ly6C<hi>, and Ly6G<hi> cells in the peritoneal lavage fluid. (B) RT-PCR analysis of IRF7 and Mx1 expression in total PECs. P values were determined by Student's t test. (C) Percentages of splenic CD11b<sup>+</sup>, Ly6C<hi>, and Ly6G<hi> cell types in TMPD-treated mice. P values in A and C were determined for C57Bl/6 vs. STING<sup>−/−</sup> mice (two-way ANOVA).](image-url)
represents a homeostatic role for STING resulting from stochastic dimerization. Alternatively, low levels of cytosolic DNA, perhaps through reactivated retro-elements, may account for the homeostatic involvement of STING. The precise mechanism by which STING regulates homeostasis remains an open question. Although loss-of-function polymorphisms for STING are well described in clinical settings (44), loss-of-function mutations in Trex1, presumably leading to hyper-activation of STING, are associated with Aicardi–Goutieres syndrome. Moreover, gain-of-function mutations in STING are now linked to a class of vascular and pulmonary inflammatory syndromes as well as familial systemic diseases (45, 46). Together, these clinical observations have identified the STING pathway as a potential therapeutic target. Our data now raise a cautionary note regarding the use of such therapeutics, because they may have unintended consequences and perturb a carefully orchestrated balance between cytosolic and endosomal signaling cascades.

**Experimental Procedures**

**Generation and Characterization of Autoimmune STING-Deficient Mice.** The University of Massachusetts Medical School and Yale Institutional Animal Care and Use Committees approved all animal work.

**STING**−/− mice (3) (from G. Barber, University of Miami, Coral Gables, FL) and IRF3−/− mice (47) were crossed to Fas-deficient, lupus-prone MRL/Mp*+/−/lpr mice (Jackson Laboratory). A controlled F2 intercross between heterozygote STING+/−, lpr/− littermates was used to generate STING-deficient lupus-prone mice homozygous for deficiency in Fas as well as STING (STING/lpr, n = 17–20) or wild type for STING (WT/lpr, n = 9–15). The heterogeneous genetic composition of the F2 generation was controlled by the use of large cohorts of littermates. Most mice were analyzed at 16 wk of age; three STING/lpr mice and three WT/lpr mice were analyzed at 25 wk of age.
Statistical Analysis. Experiments are reported as the means ± SEM/SD. Statistical comparisons were made using a Student t test and GraphPad Prism software (GraphPad Software) for bivariate studies and one-way ANOVA for multivariate studies. P values for all criteria measured are reported, and P values <0.05 were considered statistically significant.

Please see SI Experimental Procedures for more information on the methods used in this study.